These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma. Matsuki E; Younes A Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488 [TBL] [Abstract][Full Text] [Related]
4. Strategies for Recognizing and Managing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors. Vardhana S; Cicero K; Velez MJ; Moskowitz CH Oncologist; 2019 Jan; 24(1):86-95. PubMed ID: 30082490 [TBL] [Abstract][Full Text] [Related]
5. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
6. Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition? Othman T; Herrera A; Mei M Curr Hematol Malig Rep; 2021 Feb; 16(1):1-7. PubMed ID: 33409966 [TBL] [Abstract][Full Text] [Related]
7. Where does PD-1 blockade fit in HL therapy? Herrera AF Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):213-220. PubMed ID: 30504313 [TBL] [Abstract][Full Text] [Related]
8. Checkpoint Inhibition: Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors in Hodgkin Lymphoma. Villasboas JC; Ansell S Cancer J; 2016; 22(1):17-22. PubMed ID: 26841012 [TBL] [Abstract][Full Text] [Related]
9. Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma. El Halabi L; Adam J; Gravelle P; Marty V; Danu A; Lazarovici J; Ribrag V; Bosq J; Camara-Clayette V; Laurent C; Ghez D Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):257-266.e3. PubMed ID: 33277223 [TBL] [Abstract][Full Text] [Related]
10. Targeting Immune System Alterations in Hodgkin Lymphoma. Grover NS; Savoldo B Curr Hematol Malig Rep; 2017 Aug; 12(4):358-369. PubMed ID: 28780614 [TBL] [Abstract][Full Text] [Related]
11. Novel Therapies in the Treatment of Hodgkin Lymphoma. Andrade-Gonzalez X; Ansell SM Curr Treat Options Oncol; 2021 Mar; 22(5):42. PubMed ID: 33755826 [TBL] [Abstract][Full Text] [Related]
12. Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab. Villasboas JC; Ansell SM Expert Rev Anticancer Ther; 2016; 16(1):5-12. PubMed ID: 26577822 [TBL] [Abstract][Full Text] [Related]
13. Advances in CD30- and PD-1-targeted therapies for relapsed or refractory Hodgkin lymphoma. Ma H; Li X; Lin M; Lv K; Zhang M; Wu X Am J Transl Res; 2021; 13(11):12206-12216. PubMed ID: 34956447 [TBL] [Abstract][Full Text] [Related]
14. Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells. Guolo F; Minetto P; Pesce S; Ballerini F; Clavio M; Cea M; Frello M; Garibotto M; Greppi M; Bozzo M; Miglino M; Passannante M; Marcolin R; Tedone E; Colombo N; Mangerini R; Bo A; Ruzzenenti MR; Carlier P; Serio A; Luchetti S; Dominietto A; Varaldo R; Candiani S; Agostini V; Ravetti JL; Del Zotto G; Marcenaro E; Lemoli RM Front Immunol; 2021; 12():753890. PubMed ID: 34804039 [TBL] [Abstract][Full Text] [Related]
15. Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma. Hradska K; Kascak M; Hajek R; Jelinek T Expert Rev Hematol; 2020 Apr; 13(4):375-392. PubMed ID: 32116068 [No Abstract] [Full Text] [Related]
16. Checkpoint Inhibition in Hodgkin Lymphoma - a Review. Bröckelmann PJ; Engert A Oncol Res Treat; 2017; 40(11):654-660. PubMed ID: 29065424 [TBL] [Abstract][Full Text] [Related]
17. New approaches to managing relapsed/refractory Hodgkin lymphoma: the role of checkpoint inhibitors and beyond. Caro J; Diefenbach C Expert Rev Hematol; 2021 Aug; 14(8):741-750. PubMed ID: 34350815 [No Abstract] [Full Text] [Related]
18. Program death inhibitors in classical Hodgkin's lymphoma: a comprehensive review. Dada R Ann Hematol; 2018 Apr; 97(4):555-561. PubMed ID: 29322203 [TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for the treatment of Hodgkin lymphoma. Donato EM; Fernández-Zarzoso M; De La Rubia J Expert Rev Hematol; 2017 May; 10(5):417-423. PubMed ID: 28359170 [TBL] [Abstract][Full Text] [Related]
20. Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma? Khan N; Moskowitz AJ Curr Hematol Malig Rep; 2017 Jun; 12(3):227-233. PubMed ID: 28488185 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]